Oğuzhan Yıldız

13PUBLICATIONS
105CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 13, 2026
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

|Jun 26, 2026
Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.

|May 27, 2026
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.

|May 27, 2026
Prognostic Role of Uric Acid-to-Albumin Ratio in Patients with Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

|Apr 01, 2026
Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.

Oğuzhan Yıldız, Hakan Şat Bozcuk, Melek Karakurt Eryılmaz

|Feb 27, 2026
Prognostic Significance of Albumin-Bilirubin (ALBI) Score in Gastric Cancer Patients Undergoing Curative Resection Followed by Adjuvant Therapy.

Talat Aykut, Oğuzhan Yıldız, Bahattin Engin Kaya

Pageof 3

Frequent Collaborators

9 joint publications

Murat Araz

9 joint publications

Mehmet Artaç

7 joint publications

Melek Karakurt Eryılmaz

6 joint publications

Talat Aykut